Navigation Links
NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference

AMES, Iowa, April 25, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that Nicholas N. Vahanian , M.D., NewLink's Chief Medical Officer, is scheduled to present at the Needham and Company 12th Annual Healthcare Conference in New York on Tuesday, April 30, 2013 at 12:50 p.m. ET.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for cancer patients.  NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications.  NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens.  NewLink's lead product candidate, algenpantucel-L (HyperAcute® Pancreas) is being studied in a Phase 3 clinical trial in surgically resected pancreatic cancer patients (under a Special Protocol Assessment with the U.S. FDA) as well as in a separate study in locally advanced pancreatic cancer patients.  NewLink has recently launched an adaptive design Phase 2B/3 clinical trial of tergenpumatucel-L (HyperAcute® Lung) in patients with non-small cell lung cancer.  NewLink is developing indoximod, a small molecule, orally bioavailable product candidate from NewLink's proprietary indoleamine-(2,3)-dioxygenase, or IDO, pathway inhibitor technology.  NewLink is studying indoximod in various chemotherapy and immunotherapy combination studies independently and in collaboration with the National Cancer Institute.  For more information please visit  Patient information is available at

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "target", "potential", "will", "could", "should", "seek", or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about: the prospects of algenpantucel-L, indoximod and our other HyperAcute product candidates and related clinical trials. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including risks relating to: the initiation of clinical trials and the completion of enrollment; adverse general economic and industry conditions; and those risks discussed in "Risk Factors" and elsewhere in NewLink's Annual Report on Form 10-K for the period ended December 31, 2012, Form S-3 Registration Statement filed December 28, 2012 and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release represent NewLink's views as of the date of this press release. NewLink anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink's views as of any date subsequent to the date of this press release.


Gordon Link 
Chief Financial Officer 

SOURCE NewLink Genetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lota S. Zoth joins NewLinks Board of Directors; heads Audit Committee
2. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
3. NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock
4. NewLink Genetics Corporation Announces Pricing of Public Offering of Common Stock
5. NewLink Genetics Corporation Announces Exercise of Underwriters Option and Closing of Public Offering of Common Stock
6. NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call
7. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
8. Intermountain Healthcare and Myriad Genetics Enter Into Research Collaboration Agreement
9. Genelex Receives First Patent on Business Methods for Pharmacogenetics
10. Response Genetics, Inc. to Release Second Quarter Financial Results and Host Conference Call on August 14, 2012
11. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
Post Your Comments:
(Date:10/12/2015)... 12, 2015  CME Group,s Center for Innovation ... of Theranos, is the 11 th recipient of the ... revolutionary blood diagnostics company, Theranos , to change health ... a new era of preventive care. CME Group will present ... Conference in Naples, Florida , on ...
(Date:10/12/2015)... 12, 2015 --> ... Review, H2 2015 market research report provides data ... by identifying new targets and MOAs to produce ... . --> . ... across 62 pages, analyzing 6 companies, 8 drug ...
(Date:10/12/2015)... October 12, 2015 --> ... on the global vital signs monitoring devices market in its ... Analysis and Opportunity Assessment 2015-2025." The global vital signs monitoring ... of 9.5% and 9.2% in terms of value and volume, ... FMI offers major insights in detail in this report. ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... SPH Analytics today announced the following ... Executive Vice President of Operations, and three Senior Vice Presidents, Robert Davis, David ... company. , Debbie Vereb’s appointment to Executive Vice President of Operations at SPH ...
(Date:10/13/2015)... ... 2015 , ... Curly Hair Solutions® is thrilled to be ... exhibition featuring the newest products and services to hit the market for women. ... excited to unveil their recent partnership with Trade Secrets, a leading Canadian beauty ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... from GyencoloGeneTM, the world’s first commercially-available next-generation sequencing laboratory test for bacterial ... of Gynecology and Obstetrics in Vancouver, BC, Canada. , In a ...
(Date:10/13/2015)... ... October 13, 2015 , ... Doulagivers is O'Brien's ... Training and End of Life Doula Training. A Doulagiver is a non-medical ... and emotionally. Based on her #1 International bestselling book Creating Positive Passings ...
(Date:10/12/2015)... ... October 13, 2015 , ... Career Step, ... the release of its new Professional Medical Coding and Billing with Applied PCS ... ICD-10-CM and ICD-10-PCS code sets, earn the Certified Professional Coder (CPC) and Certified ...
Breaking Medicine News(10 mins):